Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 3/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 10/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226569 | 0.85 | SCN9A (0.38) | SCN9APTGER3P2RX7GCKNOTUM | |
| SCHEMBL3479665 | 0.85 | SCN9A (0.40) | SCN9ATNKSPTGER3CYP1A1CYP1B1 | |
| SCHEMBL3228368 | 0.83 | SCN9A (0.43) | SCN9AGCKNOTUMHTR6 | |
| SCHEMBL3239098 | 0.81 | SCN9A (0.44) | SCN9AGCKNOTUM | |
| SCHEMBL3479573 | 0.81 | SCN9A (0.40) | SCN9ATNKSCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL3479784 | 0.81 | SCN9A (0.42) | SCN9APTGER3 | |
| SCHEMBL3235735 | 0.81 | SCN9A (0.46) | SCN9ATNKSGCKNOTUM | |
| SCHEMBL3223503 | 0.81 | TNKS (0.38) | SCN9ATNKSP2RX7GCKNOTUM | |
| SCHEMBL3479997 | 0.81 | SCN9A (0.38) | SCN9A | |
| SCHEMBL3224788 | 0.80 | SCN9A (0.42) | SCN9ATNKSGCKNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096546-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20100137287-A1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137287-A1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ADRA1B, ADRB1, ADRA1D | SCN9A 795/4885TNKS 3292/4885PTGER3 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.